Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Rahma, Osama E ^a,c   Herrin, Vincent E ^a   Ibrahim, Rami A ^a   Toubaji, Anton ^a   Bernstein, Sarah ^b   Dakheel, Omar ^a   Steinberg, Seth M ^a   Eid, Rasha Abu ^d   Mkrtichyan, Mikayel ^d   Berzofsky, Jay A ^a   Khleif, Samir N ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cervical cancer; Dendritic cells; E6; E7; HPV16; Vaccine

Indexed keywords

CHROMIUM 51; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN E6; PROTEIN E7; CANCER VACCINE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ADULT; ADVANCED CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS REACTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MIDDLE AGED; NONHUMAN; OVERALL SURVIVAL; PRE IMMATURE DENDRITIC CELL; PROGRESSION FREE SURVIVAL; REVIEW; UTERINE CERVIX CANCER; IMMUNOLOGY; UTERINE CERVICAL NEOPLASMS;

ADULT; CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84964313465     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0353-4     Document Type: Review

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
3. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004, 22(15):3113-3119.
4. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol 2005, 23(21):4626-4633.
5. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(5):271-278.
6. Arbyn M, Dillner J: Review of current knowledge on HPV vaccination: an appendix to the European guidelines for quality assurance in cervical cancer screening. J Clin Virol 2007, 38(3):189-197.
7. Ault KA: Effect of prophylactic human papillomavirus L1 virus-likeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369(9576):1861-1868.
8. Popat S, Hughes S, Papadopoulos P, Wilkins A, Moore S, Priest K, Meehan L, Norton A, O'Brien M: Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer 2007, 56(1):135-137.
9. Regan DG, Philp DJ, Hocking JS, Law MG: Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex Health 2007, 4(3):147-163.
10. Mandic A, Vujkov T: Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann Oncol 2004, 15(2):197-200.
11. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632.
12. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K: Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004, 78(21):11451-11460.
13. Roden RB, Ling M, Wu TC: Vaccination to prevent and treat cervical cancer. Hum Pathol 2004, 35(8):971-982.
14. Samara RN, Khleif SN: HPV as a model for the development of prophylactic and therapeutic cancer vaccines. Curr Mol Med 2009, 9(6):766-773.
15. Gilboa E: DC-based cancer vaccines. J Clin Invest 2007, 117(5):1195-1203.
16. Bubenik J: Genetically engineered dendritic cell-based cancer vaccines (review). Int J Oncol 2001, 18(3):475-478.
17. Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN: A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012, 61(3):373-84.
18. Schuler G, Steinman RM: Dendritic cells as adjuvants for immunemediated resistance to tumors. J Exp Med 1997, 186(8):1183-1187.
19. Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003, 15(2):138-147.
20. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252.
21. Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Durst M, Schneider A, Kaufmann AM: Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003, 129(9):521-530.
22. Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ: HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 2006, 100(3):469-478.
23. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347(9014):1523-1527.
24. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ: Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361(19):1838-1847.